Effect of Remimazolam and Propofol on Hemodynamic Stability During Anesthesia Induction in OPCAB Patients
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Remimazolam is a novel ultra-short-acting benzodiazepine. Several studies demonstrated that
its efficacy as a sedative hypnotics for general anesthesia is non-inferior to propofol.
However, evidence on the hemodynamic stability of remimazolam for the anesthesia induction in
patients undergoing coronary artery bypass grafting is lacking. This prospective randomized
trial aims to compare hemodynamic stability during anesthesia induction between remimazolam
and propofol in patients undergoing coronary artery bypass grafting.